introduction intrahepatic cholangiocarcinoma icca hepatocellular carcinoma hcc two main histological form primary liver cancer plc among leading cause cancer-related death worldwide prevalent form cancer thailand date disease associated poor prognosis patient often present advanced non-resectable stage risk factor thai icca patient include liver fluke opisthorchis viverrini infection biliary tract disorder hepatitis virus hbv hepatitis virus hcv infection recent survey showed environmental factor combined certain genetic polymorphism could also increase risk icca risk factor hcc thai patient include hbv hcv infection alcohol consumption cirrhosis cause dietary aflatoxin environmental exposure hbv alone accounting case improve understanding disease susceptibility progression patient outcome among plc thai population thailand initiative genomics expression research liver cancer tiger-lc consortium established using stored biospecimens tiger-lc cohort previously identified several prognostic biomarkers specific thai population defined molecular subtypes icca hcc suggested possible involvement gut microbiome given connection liver intestine via portal vein individual chronic liver disease experience gut bacterial translocation liver gut microbe could involved pathogenesis progression cancer liver previous study microbiome thai plc patient focused cca helicobacter pylorus infection using tissue bile fluid sample gut microbiome advantage tumor tissue bile fluid microbiome fecal matter yield higher microbial dna biomass hence susceptible false positive exogenous dna contamination several study chinese patient compared gut microbiomes icca hcc directly however gut microbiome study icca hcc date performed microbiome profiling using rrna gene amplicon sequencing different variable region bias towards certain taxon often accurately identify bacteria specie level therefore aimed comprehensively characterize gut microbiome thai plc patient healthy control matched age sex region performed whole-genome metagenomic shotgun wgms sequencing identified different pattern dysbiosis gut microbiome icca hcc patient thai population result landscape gut dysbiosis thai plc patient healthy individual demographic clinical characteristic icca hcc group generally matched including age sex bmi common cancer risk factor supplementary table discernible difference lifestyle factor known affect gut microbiome antibiotic antifungal use among three group subject found gut microbiome profile patient icca patient hcc healthy individual similar phylum level specifically phylum firmicutes abundant bacteria overall followed bacteroides proteobacteria actinobacteria fusobacteria fig however relative abundance proteobacteria icca patient significantly higher healthy individual fig similar trend hcc patient full list comparison disease group phylum shown supplementary table although alpha diversity measure three group subject statistically different range shannon–wiener diversity index inverse simpson index taxonomic level icca consistently larger hcc fig indicating higher heterogeneity gut bacterial community icca term beta diversity among sample statistically significant difference cancer healthy control group based bray–curtis distance metric using non-negative multidimensional scaling principal coordinate analysis fig stratified analysis based sex region residence showed bias sex supplementary fig table region supplementary fig table summary result demonstrated significant difference alpha beta diversity among icca hcc healthy control group trend towards higher diversity icca additionally phylum level patient icca exhibited higher relative abundance proteobacteria healthy individual figure gut dysbiosis thai icca hcc patient different pattern relative abundance top five phylum stool sample healthy control hcc icca group relative abundance top five phylum comparing among group subject alpha diversity measure among group subject beta diversity measure among group subject based bray–curtis distance metric full size image linear discriminant analysis identifies taxon specific patient condition identify taxon could differentiate cancer group healthy control utilized alternative approach phylum-level data insufficient applied linear discriminant analysis lda metagenomic read disease condition label using lda effect size lefse identified taxon mainly phylum firmicutes actinobacteria proteobacteria uniquely present group subject log lda score fig supplementary table family veillonellaceae lactobacillales actinomycetaceae streptococcaceae neisseriaceae found differentiate icca sample group fig meanwhile family lachnospiraceae eubacteriaceae order clostridiales able distinguish healthy control sample cancer group fig notably microbe family level could distinguish hcc sample group however genus flavonifractor identified hcc-specific taxon complete list taxon identified lefse presented supplementary fig table figure lda identifies taxon differentiate disease condition overall taxon dendrogram show relationship relative distance taxon differentiate group subject log lda score four selected taxon differentiate icca healthy control sample group subject full size image specie level top five enriched specie icca group veillonella atypica bacteroides cag530 streptococcus parasanguinis veillonella parvula megasphaera micronuciformis supplementary fig top five enriched specie healthy control group bacteroides uniformis anaerostipes hadrus blautia wexlerae roseburia intestinalis phascolarctobacterium faecium supplementary fig finally top five enriched specie hcc group ruminococcus gnavus bifidobacterium longum ligilactobacillus salivarius streptococcus anginosus group bacteroides finegoldii supplementary fig result underscore potential using gut microbiome family level differentiate patient group especially patient icca reveal distinct pattern species-level composition group subject lda-identified specie verified sequence alignment assembly-based metagenomic method confirm accuracy lda result additional approach necessary marker gene-based method tends sacrifice accuracy speed employed two verification approach list specie uniquely present group subject first top three lda-identified specie group selected metagenomic read aligned complete and/or representative genome presence nine selected specie respective sample group confirmed fig a–c three specie specific icca namely atypica parvula parasanguinis exhibited highest mean read coverage icca sample particularly veillonella specie compared hcc healthy control sample fig a–c full list mean sequencing coverage nine specie shown supplementary table mean read coverage sample along full genome shown supplementary fig second validation approach metagenomic read subjected assembly based metagenomic analysis obtain metagenome-assembled genome mag fourteen mag called matched lda-identified specie except bacteroides finegoldii supplementary table based absolute abundance mag five eight icca-specific mag able distinguish icca group fig supplementary table notably two mag mag320 mag408 matching atypica could differentiate icca sample hcc healthy control group two three hcc-specific specie could differentiate hcc sample group fig supplementary table four mag called control-specific specie distinguished healthy control sample group fig supplementary table although result two verification method match perfectly statistical significance level trend direction change consistent therefore result validate presence specie identified lda including disease-specific specie ability differentiate diseased sample healthy control sample figure verification lda-identified specie sequence alignment assembly-based metagenomic method read coverage sequencing depth metagenomic read aligned complete and/or representative genome lda-identified specie top bottom boxplot specie name name complete and/or representative genome used sequence alignment respectively log absolute abundance mag called matched icca-specific hcc-specific healthy control-specific specie panel top bottom boxplot specie name mag number called matched lda-identified specie respectively full size image pathway analysis reveals differently enriched metabolic pathway icca hcc functional analysis icca hcc sample conducted using microbial read serum metabolite data genus blautia found associated four microbial pathway m1-m2 enriched hcc whereas six microbial pathway m3-m6 associated genus veillonella enriched icca fig six serum metabolic pathway overlapped microbial pathway two pathway s1-s2 associated hcc four pathway s3-s6 associated icca fig phosphoglycerolipid metabolism m1.1-m1.3 thiamine metabolism pathway enriched hcc amino acid metabolism m3.1-m3.3 nucleotide metabolism glycolysis pathway enriched icca supplementary table s10 figure microbial serum metabolic pathway show different contribution cancer group different genus top enriched microbial pathway pathway m1-m6 overlapped enriched pathway serum metabolite pathway panel scatterplot msea global test serum metabolite data comparing icca hcc patient tiger-lc discovery cohort circle size reflects pathway impact score pathway s1-s6 overlapped enriched pathway metagenomics data panel full pathway name listed supplementary table s10 relative abundance gene contribution genus associated enriched microbial pathway panel pathway genus blautia pathway m3-m6 genus veillonella log absolute abundance serum metabolite enriched metabolic pathway panel metabolite shown figure statistically different metabolite based fdr-adjusted p-values full size image also investigated difference contribution microbial gene hcc icca group shown fig relative abundance microbial gene contribution genus blautia statistically higher hcc veillonella displayed higher relative abundance icca group furthermore observed similar trend absolute abundance serum metabolite serum metabolic pathway albeit lesser degree specifically glycerophospholipid metabolism pathway equal number metabolite statistically different hcc icca whereas thiamine metabolism pathway one metabolite cysteine statistically higher hcc fig contrast pathway metabolite statistically higher hcc group whereas metabolite pathway statistically higher icca group fig supplementary table s10 furthermore analysis covariance ancova using disease status risk factor covariates predict metabolite outcome showed none risk factor listed table found confounding factor metabolite supplementary table s11 taken together result suggest gut microbiome may metabolic consequence patient finding provide insight difference icca hcc discussion previous study examining gut microbiome chinese cohort icca hcc high-risk healthy control subject demonstrated significant difference alpha beta diversity group alpha diversity measure relative abundance main phylum gut microbiome show statistical difference early hcc control group hbv-related hcc control group primary cca control group relative abundance gut microbiome phylum level particularly phylum firmicutes bacteroidetes shown differ diseased control group study using rrna sequencing finding observed data several technical issue may contributed discrepancy gut microbiome study utilization rrna sequencing sequencing different variable region yield different taxon recovery accuracy rate taxon identification resulting conflicting evidence additionally difference database used calling taxon affect accuracy taxon recovery rrna sequencing contrast wgms sequencing may accurate term number recovered taxon accuracy previous study found different sequencing method alone explain discrepancy alpha diversity human infant gut microbiome furthermore gut microbiome known influenced diet observed thai population although difference etiology geographical area lead inconsistency study observe difference region within thailand associated different food intake pattern thus assessment gut microbiome healthy cohort various region thailand using wgms provide clearer understanding relationship diet gut microbiome veillonella identified gut microbiome patient biliary tract disease primary sclerosing cholangitis psc biliary atresia liver fluke infection study also observed increased veillonella sp. specifically atypica parvula gut patient icca similarly study nonalcoholic steatohepatitis nash patient identified veillonella genus biomarker treatment response hormone analog additionally higher relative abundance family veillonellaceae found cohort chinese patient cca genus veillonella one eight-genera predictive signature differentiate cca hcc healthy control group taken together result study suggest increased veillonella gut particularly atypica associated biliary tract disease could potentially serve fecal biomarker cca notably increased level genus veillonella streptococcus reported saliva cca patient compared healthy control suggesting specie found gut study might migrated mouth gut patient although underlying mechanism remains unknown study performed microbial gene contribution functional analysis microbiome data reason might study used rrna sequencing conclusion interpretation drawn pathway analysis result based rrna data limited enriched microbial pathway found study known altered various disease including cancer example several serum metabolite glycerophospholipid metabolism pathway identified hcc-specific metabolite previous study stearoyl-linoleoyl-glycerophosphocholine palmitoyl-linoleoyl-glycerophosphocholine 2-palmitoylglycerophosphocholine 1-arachidonoylglycerophosphocholine enrichment veillonella gut correlated enhanced marathon running performance via atypica capacity metabolize serum lactate entered gut lumen resulting generation acetate propionate however infer association serum microbiome data obtained different patient study profiled microbiome metabolite together fecal sample class metabolite measured limited one class metabolite therefore comprehensive metabolomic profiling directly fecal sample together microbiome profiling patient needed better understand association microbiome metabolic consequence cancer scope study limited absence sample intermediate- high-risk patient group infection primary sclerosing cholangitis psc icca hbv/hcv infection liver cirrhosis chronic liver disease cld nonalcoholic steatohepatitis nash nonalcoholic fatty liver disease nafld hcc studying microbiomes high-risk group might help discern whether certain specie indeed associated primary liver cancer addition direct comparison result study might possible meaningful due difference sequencing method furthermore infection status sample inferred questionnaire rather definitive test ovum parasite stool examination although diagnosis time recruitment icca patient suggested intrahepatic origin cca tissue definitively exclude presence infection fecal sample since ov-pcr test requires substantial amount fecal material modified dna extraction protocol obtain ov-dna breaking ov-egg thin smear stool collection method employed study using fobt card lack sufficient material ov-pcr test finally number sample cancer group limited analysis larger sample size needed conclusion study indicates gut dysbiosis landscape disease-specific fecal microbial specie differ icca hcc patient microbial specie may hold potential noninvasive biomarkers early detection primary liver cancer material method patient recruitment specimen collection stool sample patient collected clinical center northern northeastern central thailand cohort consisted icca hcc healthy individual matched age sex region residence cancer case clinical socioeconomic demographic data extracted comprehensive questionnaire medical record collected time recruitment patient icca diagnosed using combination imaging histological investigation hcc patient diagnosed using combination imaging study tumor size alpha-fetoprotein afp level histological investigation healthy control individual without history cancer mostly recruited regular physical checkup routine procedure informed consent obtained patient included study protocol approved institutional review board respective institution nci protocol number 13cn089 cri protocol number 18/2555 chulabhorn hospital protocol number 11/2553 thai nci protocol number ec163/2010 chiang mai university protocol number tiger-lc khon kaen university protocol number he541099 fecal sample collected prior treatment hema-screen occult blood rapid test card stanbio laboratory boerne usa according manufacturer instruction card kept without processing dna extraction wgms sequencing one square fecal occult blood test card containing thin smear stool sample placed bead-beating tube microbial dna extracted using zymobiomics dna miniprep kit zymo research irvine usa according manufacturer protocol sequencing library construction microbial dna prepared random fragmentation followed adapter ligation using nextera dna library preparation kit illumina san diego usa wgms performed one lane flow cell using novaseq platform illumina read length base pair paired-end mode average yield per sample approximately million read data pre-processing multiqc used sequence quality check trimmomatic used sequencing adapter trimming step average number read passed q30 approximately million per sample host-genome removal step performed aligning read human genome version grch38 using bowtie2 yielded average million read per sample used downstream analysis data deposited ncbi sra accession number prjna932948 marker gene-based metagenomic analysis centrifuge metaphlan3 used perform marker gene-based metagenomic analysis default setting centrifuge run database derived ncbi nucleotide database includes human prokaryote viral complete sars-cov-2 genome database dated march approximately read classified microbial metaphlan3 run using chocophlan database version 201901b linear discriminant analysis lda performed using lda effect size lefse default setting identify taxon could differentiate sample group top three specie group selected verification sequence alignment complete and/or representative genome complete and/or representative genome top three specie selected lda disease condition retrieved ncbi database priority given complete genome classification representative genome designation complete genome available representative genome used complete representative genome used study listed supplementary table representative complete genome contigs concatenated one fasta file metagenomic read aligned fasta file bwa-mem2 used sequence alignment result sequence alignment visualized mean sequencing depth specie disease condition calculated anvi assembly-based metagenomic analysis assembly based metagenomic analysis performed using atlas collection tool based snakemake pipeline language pipeline run sequentially sample generate single combined metagenome-assembled genome mag library contained specie present sample boxplots absolute abundance mag matched closely related selected specie lda generated using ggplot2 package microbial metabolic pathway analysis data metaphlan3 used functional potential profiling microbial community using humann3 based uniref gene family database metacyc metabolic pathway database association sample metadata functional potential data determined using maaslin2 hcc group used reference p-values association adjusted multiple hypothesis testing using false discovery rate fdr correction holm-bonferroni procedure top enriched microbial metabolic pathway selected serum metabolite data tiger-lc discovery cohort previous study used perform metabolite set enrichment analysis msea icca hcc group using global test empirical bayesian generalized linear model metaboanalyst 5.0 platform kegg pathway database hcc group used reference group enriched microbial serum metabolic pathway involved process deemed overlapping pathway microbial serum metabolite statistical analysis statistical analysis performed using version 4.0 shannon–wiener diversity index inverse simpson index within-sample alpha diversity bray–curtis distance between-sample beta diversity calculated using vegan package stacked bar plot box plot non-metric multidimensional scaling nmds principal coordinate analysis pcoa plot generated using ggplot2 reported p-values two-sided p-values calculated wilcoxon rank-sum test mann–whitney test group using rstatix package fdr correction using holm-bonferroni procedure confounding factor correction serum metabolomics data calculated ancova statement ethic written informed consent obtained patient included study accordance declaration helsinki good clinical practice guideline study protocol approved institutional review board respective institution nci protocol number 13cn089 cri protocol number 18/2555 chulabhorn hospital protocol number 11/2553 thai nci protocol number ec163/2010 chiang mai university protocol number tiger-lc khon kaen university protocol number he541099